<DOC>
	<DOCNO>NCT00442052</DOCNO>
	<brief_summary>Primary : To compare gastroprotective effect once-daily dose PA 325 combination tablet combine 325 mg pH sensitive aspirin 20 mg immediate release omeprazole versus once-daily dose 325 mg enteric coat aspirin utilizing Lanza score endoscopy finding normal healthy volunteer .</brief_summary>
	<brief_title>To Compare Gastroprotective Effects Pharmacokinetic Profile PA Versus Enteric-Coated Aspirin</brief_title>
	<detailed_description>PA 325 propose reduction risk aspirin-associated gastrointestinal ( GI ) adverse event patient require daily aspirin . This study design Proof Concept study evaluate gastroprotective effect , pharmacokinetic profile , safety PA 325 healthy volunteer . To compare gastroprotective effect once-daily dose PA 325 combination tablet combine 325 mg pH-sensitive aspirin 20 mg immediate release omeprazole versus once-daily dose 325 mg enteric coat aspirin utilizing Lanza score endoscopy finding normal healthy volunteer .</detailed_description>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>1 . A subject eligible inclusion study follow criterion apply : Subject male nonpregnant female Subject 5075 year age Subject currently smoke Physical status within normal limit age consistent observation screen BMI 2030 kg/m2 2 . Female subject eligible participation study : Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) ; , Childbearing potential , negative pregnancy test ( urine ) screening , least one follow applies agree subject : Complete abstinence intercourse least 14 day prior first dose study medication , throughout study , 30 day completion study Female sterilization sterilization male partner ; , Hormonal contraception oral route , implant , injectable , vaginal ring ; , Any intrauterine device ( IUD ) publish data show low expected failure rate le 1 % per year ; Double barrier method ( 2 physical barrier 1 physical barrier plus spermicide ) ; Any method publish data show low expected failure rate le 1 % per year 3 . Each subject must able understand comply study procedure require subject able willing provide write informed consent prior study procedure perform 1 . History hypersensitivity omeprazole another protonpump inhibitor 2 . History allergic reaction intolerance aspirin NSAIDs and/or subject history NSAIDinduced symptom asthma , rhinitis , and/or nasal polyp 3 . Participation study investigational treatment 4 week Day 1 dose 4 . Presence uncontrolled acute chronic medical illness , e.g . gastrointestinal disorder , diabetes , hypertension , thyroid disorder , depression and/or infection would endanger subject participate study 5 . Gastrointestinal disorder surgery lead impaired drug absorption 6 . Evidence uncontrolled , unstable cardio cerebrovascular disorder , investigator ’ opinion would endanger subject participate study 7 . Schizophrenia bipolar disorder 8 . Use concomitant medication approve study physician washout period study conduct 9 . Serious blood coagulation disorder include use systemic anticoagulant 10 . Subjects donate 50 499 mL blood within 30 day 499 mL within 56 day prior dose 11 . Subjects , completion study , would donate excess : 500 mL blood 14 day ; 1,500 mL blood 180 day ; 2,500 mL blood 1 year . 12 . Baseline endoscopy show gastric duodenal mucosal abnormality ( hemorrhage , ulcer erosion ) 13 . Gastric pH &gt; 3 screen 14 . Screening laboratory value ALT , AST &gt; 2 time upper limit normal 15 . Estimated creatinine clearance &lt; 30 ml/min 16 . Other note specifically , screen laboratory value clinically significant investigator ’ opinion would endanger subject participate study 17 . History hepatitis B C , positive test hepatitis B surface antigen , hepatitis C antibody , history HIV infection , demonstration HIV antibodies 18 . History malignancy , treat untreated , within past 5 year , exception successfully treat basal cell squamous cell carcinoma skin 19 . Subjects previously screen failure study 20 . Subject excessive alcohol use ( &gt; 2 unit per day average ; example 2 bottle beer , two glass wine , 2 ounce liquor/spirits ) , recent history ( past 3 month ) suggestive alcohol drug abuse dependence . 21 . Subject ingested grapefruit grapefruit juice within 10 day dose ingest grapefruit grapefruit juice duration study . 22 . Positive illicit drug screen</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Gastroprotective effect</keyword>
	<keyword>Aspirin</keyword>
</DOC>